|
|
| This month: The cathepsin K inhibitor odanacatib, a novel approach to the treatment of osteoporosis |
 |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
235th ACS National Meeting
New Orleans, LA,
6-10 April 2008
Visit us at booth 400 and find out more about Prous Science Integrity new developments. |
|
|
|
|
  Available:
Webcasts from the European Association of Urology (EAU)
March 26 - 29, 2008
Milan, Italy |
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anxiety Targetscape:
A comprehensive network of molecular and cellular connections among the current therapeutic targets for the treatment of anxiety, and their biological actions |
|
|
|
|
 International Society Cardiovascular Pharmacotherapy
The ISCP is a society devoted to education and medical research in the field of cardiovascular pharmacotherapy, as well as to the international exchange of information and to the needs of cardiovascular pharmacotherapy with special focus on developing countries. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Drugs of the Future
POEMS syndrome, a rare disorder associated with a poor prognosis, can often be treated effectively with radiation therapy, alkylating agents and stem cell transplantation, but other therapeutic options are under investigation in order to standardize treatment.
|
|
|
Drug News & Perspectives
Targeting biological pathways in abdominal aortic aneurysm (AAA), a complex multifactorial disease with life-threatening implications, may benefit patients by slowing the growth and possibly preventing the rupture of AAA.
|
|
|
|
